In his monthly column for Omnicell’s blog, 340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022. They focus on:
- the U.S. Supreme Court case on Medicare reimbursement to 340B hospitals
- where the contract pharmacy standoff is ultimately headed
- next steps in the effort by 340B providers to challenge what they perceive as discriminatory reimbursement by third party payors as well as the congressional effort to establish a neutral clearinghouse to resolve the duplicate discount challenge.
You can read the piece here.